FNDC3B promotes epithelial-to-mesenchymal transition and activates multiple cancer pathways, for example, in squamous cell carcinoma, acute promyelocytic leukemia, and hepatocellular carcinoma [14–17]. Here, FNDC3B is linked to cancer.